Neuroprotective Potential of Peroxisome Proliferator Activated Receptor-α Agonist in Cognitive Impairment in Parkinson’s Disease: Behavioral, Biochemical, and PBPK Profile

Figure 2

(a) Effect of fenofibrate on MDA and (b) GSH level in different groups. ^∗∗∗𝑃<0.001 MPTP versus sham, ^###𝑃<0.001 MPTP versus feno 10 mg/kg, feno 30 mg/kg and feno 100 mg/kg treated groups, ^@@@𝑃<0.001 MPTP + vehicle versus sham and ^†††𝑃<0.001 MPTP + vehicle versus feno 100 mg/kg group, ^††𝑃<0.01 MPTP + vehicle versus feno 30 mg/kg treated group. All readings are expressed as mean ± SEM (𝑛=8 to 12).

(a)

(b)